Literature DB >> 23755536

[Methylation profile of group of miRNA genes in clear cell renal cell carcinoma; involvement in cancer progression].

E V Beresneva, S V Rykov, D S Hodyrev, I V Pronina, V D Ermilova, T P Kazubskaia, E A Braga, V I Loginov.   

Abstract

MicroRNA regulates gene expression, is involved in many cellular processes, and plays an important role in the development of cancer. The regulation of the expression of miRNA genes can be achieved by methylating their CpG islands, which is shown in different types of tumors. The methylation of miRNA genes in clear cell renal cell carcinoma (CCRCC) has mainly been studied for the miR-9 and miR-34 families. The methylation of six miRNA genes (miR-124a-2, -124a-3, -9-1, -9-3, -34b/c, -129-2) was investigated with the use of representative set of CCRCC samples (46 cases). Methylation of three genes miR-124a-2, -124a-3, and -129-2 was studied in kidney tumors for the first time. Methylation analysis was performed using methyl specific PCR. It is shown that the frequency of methylation of six genes (miR-124a-2, -124a-3, -9-1, -9-3, -34b/c and -129-2) was significantly higher in tumor samples than in samples of histologically normal tissue (P < 3 x 10(-5) by Fisher's exact test). These results suggest the properties of tumor suppressors for the six miRNA genes indicated in CCRCC. We also found correlations between the methylation frequency of some miRNA genes and signs of the progression of CCRCC (tumor size, clinical stage, loss of differentiation, and metastasis).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23755536     DOI: 10.7868/s001667581303003x

Source DB:  PubMed          Journal:  Genetika        ISSN: 0016-6758


  7 in total

1.  MicroRNA-877 acts as a tumor suppressor by directly targeting eEF2K in renal cell carcinoma.

Authors:  Qianqian Shi; Xianlin Xu; Qing Liu; Fengbao Luo; Jian Shi; Xiaozhou He
Journal:  Oncol Lett       Date:  2015-12-31       Impact factor: 2.967

Review 2.  MicroRNAs in renal cell carcinoma: a systematic review of clinical implications (Review).

Authors:  Ming Li; Ying Wang; Yongsheng Song; Renge Bu; Bo Yin; Xiang Fei; Qizhen Guo; Bin Wu
Journal:  Oncol Rep       Date:  2015-02-13       Impact factor: 3.906

Review 3.  MicroRNA-34 family in breast cancer: from research to therapeutic potential.

Authors:  Saber Imani; Ray-Chang Wu; Junjiang Fu
Journal:  J Cancer       Date:  2018-09-28       Impact factor: 4.207

4.  miR-4478 sensitizes ovarian cancer cells to irradiation by inhibiting Fus and attenuating autophagy.

Authors:  Lingling Wang; Ying Liu; Haixia Li; Cui Zhang; Hongbo Wang; Shaochun Dai; Wen Cheng; Yan Sun; Xiulan Zheng
Journal:  Mol Ther Nucleic Acids       Date:  2020-12-03       Impact factor: 8.886

5.  MicroRNA-375 Suppresses the Tumor Aggressive Phenotypes of Clear Cell Renal Cell Carcinomas through Regulating YWHAZ.

Authors:  Xiang Zhang; Nai-Dong Xing; Cheng-Jun Lai; Rui Liu; Wei Jiao; Jue Wang; Jie Song; Zhong-Hua Xu
Journal:  Chin Med J (Engl)       Date:  2018-08-20       Impact factor: 2.628

6.  ADH7, miR-3065 and LINC01133 are associated with cervical cancer progression in different age groups.

Authors:  Shengdi Ding; Xiaohong Huang; Junmei Zhu; Bing Xu; Limin Xu; Donghua Gu; Wenyuan Zhang
Journal:  Oncol Lett       Date:  2020-01-24       Impact factor: 2.967

7.  miR-124 and miR-203 synergistically inactivate EMT pathway via coregulation of ZEB2 in clear cell renal cell carcinoma (ccRCC).

Authors:  Jiajia Chen; Yuqing Zhong; Liangzhi Li
Journal:  J Transl Med       Date:  2020-02-11       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.